ciliary rootlet coiled-coil, rootletin family member 2Genealiases: []
Q-omics provides the consensus-scored CROCC2 profile across patient tissues and cancer cell-line models. CROCC2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CROCC2 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, CROCC2 RNA expression shows 15,313 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, LUSC, and UVM as cancer lineages where CROCC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CROCC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CROCC2 survival associations across molecular data types. CROCC2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CROCC2 RNA expression–survival associations across cancer types. High CROCC2 expression shows unfavorable associations in THCA, UVM, COAD and KIRC, but favorable associations in PAAD and HNSC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify THCA as the clearest survival context for CROCC2 RNA expression.
This table summarizes CROCC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CROCC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CROCC2 shows lower tumor expression in LUSC, LUAD, LIHC, KICH, READ and THCA. The LUSC box plot shows higher CROCC2 RNA expression in normal versus tumor tissue (log2 FC = −0.996, t-test p < 0.001).
This table shows molecular features associated with CROCC2 in patient tissues and cancer cell lines. In patient samples, CROCC2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CROCC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
